Cancer Database Query Results

Ovarian, Ovarian Cancer: Click to Expand ⟱
Ovarian Cancer
Scientific Papers found: Click to Expand⟱
5459- AF,    Auranofin Induces Lethality Driven by Reactive Oxygen Species in High-Grade Serous Ovarian Cancer Cells
- in-vitro, Ovarian, NA
ROS↑, TrxR↓, MMP↓, Apoptosis↑, eff↓, Casp3↑, Casp7↑, DNAdam↑, eff↑, GSH↓, angioG↓, ChemoSen↑, cl‑PARP↑, eff↑,
5977- AgNPs,  CDT,    Silver Nitroprusside as an Efficient Chemodynamic Therapeutic Agent and a Peroxynitrite nanogenerator for Targeted Cancer Therapy
- in-vivo, Ovarian, A2780S - NA, Ovarian, SKOV3
Fenton↑, ROS↑, eff↑, angioG↓, p‑Akt↓, EPR↑, selectivity↑, selectivity↑, eff↑, Cyt‑c↑, HO-1↑,
4389- AgNPs,    Graphene Oxide-Silver Nanocomposite Enhances Cytotoxic and Apoptotic Potential of Salinomycin in Human Ovarian Cancer Stem Cells (OvCSCs): A Novel Approach for Cancer Therapy
- in-vitro, Ovarian, NA
tumCV↓, ROS↑, LDH↓, MMP↑, CSCs↓, AntiCan↑,
4563- AgNPs,  Rad,    Silver nanoparticles enhance neutron radiation sensitivity in cancer cells: An in vitro study
- in-vitro, BC, MCF7 - in-vitro, Ovarian, SKOV3 - in-vitro, GBM, U87MG - in-vitro, Melanoma, A431
RadioS↑, ROS↑, TumCCA↑, Apoptosis↑, ER Stress↑,
4539- AgNPs,  VitC,  Citrate,    Investigating the Anti-cancer Potential of Silver Nanoparticles Synthesized by Chemical Reduction of AgNO3 Using Trisodium Citrate and Ascorbic Acid
- in-vitro, Nor, L929 - in-vitro, Ovarian, SKOV3
AntiCan↑,
322- AgNPs,  Cisplatin,    Heterogeneous Responses of Ovarian Cancer Cells to Silver Nanoparticles as a Single Agent and in Combination with Cisplatin
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, OVCAR-3
ROS↑, DNAdam↑, GSH/GSSG↓,
358- AgNPs,    Preparation of triangular silver nanoparticles and their biological effects in the treatment of ovarian cancer
- vitro+vivo, Ovarian, SKOV3
TumCCA↑, ROS↑, Casp3↑, TumCG↓, cycD1/CCND1↓,
397- AgNPs,  GEM,    Silver nanoparticles enhance the apoptotic potential of gemcitabine in human ovarian cancer cells: combination therapy for effective cancer treatment
- in-vitro, Ovarian, A2780S
P53↑, P21↑, BAX↑, Bak↑, Cyt‑c↑, Casp3↑, Casp9↑, Bcl-2↓, ROS↑, MMP↓,
299- ALA,  Cisplatin,  PacT,    Anti-cancer effects of alpha lipoic acid, cisplatin and paclitaxel combination in the OVCAR-3 ovarian adenocarcinoma cell line
- in-vitro, Ovarian, OVCAR-3
MMP9↓, MMP11↓, MAPK↓,
266- ALA,    Lipoic acid decreases Mcl-1, Bcl-xL and up regulates Bim on ovarian carcinoma cells leading to cell death
- in-vitro, Ovarian, IGROV1
Mcl-1↓, Bcl-xL↓, BIM↑, ROS↑,
7394- Amla,    Emblica officinalis extract downregulates pro-angiogenic molecules via upregulation of cellular and exosomal miR-375 in human ovarian cancer cells
- vitro+vivo, Ovarian, NA
antiNeop↑, TumCP↓, TumCMig↓, TumCI↓, TumCG↓, miR-375↑, IGFR↓, Snail↓, E-cadherin↑,
7393- Amla,    Emblica officinalis extract induces autophagy and inhibits human ovarian cancer cell proliferation, angiogenesis, growth of mouse xenograft tumors
- vitro+vivo, Ovarian, OVCAR-3 - in-vitro, Ovarian, SW626
TumCP↓, Beclin-1↑, LC3B-II↑, Hif1a↓, Dose↝, TumAuto↑, angioG↓, COL4A3↓, CXCL6/GCP-2↓, TYMP/ECGF1↓, IL1β↓, PDGFRB↓, ChemoSen↑, Dose↝,
577- Api,  PacT,    Inhibition of IL-6/STAT3 axis and targeting Axl and Tyro3 receptor tyrosine kinases by apigenin circumvent taxol resistance in ovarian cancer cells
- in-vitro, Ovarian, SKOV3
p‑Akt↓, Bcl-xL↓, Bcl-2↓, AXL↓, Tyro3↓,
275- Api,    Apigenin inhibits the self-renewal capacity of human ovarian cancer SKOV3‑derived sphere-forming cells
- in-vitro, Ovarian, SKOV3
HH↓, CK2↓, Gli1↓,
273- Api,    Apigenin inhibited migration and invasion of human ovarian cancer A2780 cells through focal adhesion kinase
- in-vivo, Ovarian, A2780S
FAK↓,
1147- ART/DHA,    Inhibitory effects of artesunate on angiogenesis and on expressions of vascular endothelial growth factor and VEGF receptor KDR/flk-1
- vitro+vivo, Ovarian, HO-8910 - vitro+vivo, Nor, HUVECs
angioG↓, TumCG↓, VEGF↓, VEGFR2/KDR/Flk1↓, *toxicity↓,
1028- ASA,    Aspirin Suppressed PD-L1 Expression through Suppressing KAT5 and Subsequently Inhibited PD-1 and PD-L1 Signaling to Attenuate OC Development
- vitro+vivo, Ovarian, NA
TumCP↓, TumW↓, PD-L1↓, Ki-67↓, H3K27ac∅, eff↑,
1363- Ash,  doxoR,    Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer
- in-vitro, Ovarian, A2780S - in-vitro, Ovarian, CaOV3 - in-vivo, NA, NA
ChemoSen↑, ROS↑, DNAdam↑, TumCCA↑, LC3B↑, TumCG↓, cl‑Casp3↑,
4660- Ash,    Withaferin A Alone and in Combination with Cisplatin Suppresses Growth and Metastasis of Ovarian Cancer by Targeting Putative Cancer Stem Cells
- in-vitro, Ovarian, NA
CSCs↓, TumCG↓, TumMeta↓, CD44↓, CD34↓, OCT4↓, NOTCH1↓, HEY1↓,
4677- Ash,    Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells
- vitro+vivo, Ovarian, NA
CSCs↓, Securin↓, ALDH1A1↓,
3157- Ash,    Withaferin A and Ovarian Cancer Antagonistically Regulate Skeletal Muscle Mass
- in-vivo, Ovarian, A2780S
*cachexia↑, *UPR↑, Strength↑,
4982- ATV,    Inhibiting the mevalonate pathway with atorvastatin alters gut microbiota and has potential as an anti-cancer treatment for ovarian cancer
- in-vivo, Ovarian, NA
HMG-CoA↓, GutMicro↑,
1520- Ba,    Baicalein Induces G2/M Cell Cycle Arrest Associated with ROS Generation and CHK2 Activation in Highly Invasive Human Ovarian Cancer Cells
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, TOV-21G
TumCG↓, TumCCA↑, ROS↑, DNAdam↑, Chk2↑, Dose∅, p‑γH2AX↑, CDC25↓, CHK1↓, cycD1/CCND1↓, eff↓, 12LOX↓,
1381- BBR,  Rad,    Berberine enhances the sensitivity of radiotherapy in ovarian cancer cell line (SKOV-3)
- in-vitro, Ovarian, SKOV3
RadioS↑, ROS↑, GSH↓, Apoptosis↑,
2710- BBR,    Berberine inhibits the Warburg effect through TET3/miR-145/HK2 pathways in ovarian cancer cells
- in-vitro, Ovarian, SKOV3
Warburg↓, miR-145↑, HK2↓, TET3↑, Glycolysis↓, PKM2↓, GLUT1↓, LDH↓, PFK2↓, PDK1↓,
6500- BCP,    Beta-Caryophyllene Suppresses Ovarian Cancer Proliferation by Inducing Cell Cycle Arrest and Apoptosis
- in-vitro, Ovarian, NA
TumCP↓, TumCCA↑, Apoptosis↑, Casp3↑, cl‑PARP↑,
722- Bor,    Boric acid as a promising agent in the treatment of ovarian cancer: Molecular mechanisms
- in-vitro, Ovarian, MDAH-2774
TumCP↓, TumCI↓, TumCMig↓, Apoptosis↑, ROS↑, miR-21↓, miR-130a↓, Casp8∅, Casp10∅, cycD1/CCND1∅, CDK6∅, CDK4∅, FADD∅, DR4∅, DR5∅,
1297- CA,    Caffeic Acid Phenethyl Ester (CAPE) Induced Apoptosis in Serous Ovarian Cancer OV7 Cells by Deregulation of BCL2/BAX Genes
- in-vitro, Ovarian, OV7
lysosome↓, Apoptosis↑, Bax:Bcl2↑,
5941- Cela,    Celastrol inhibits migration and invasion through blocking the NF-κB pathway in ovarian cancer cells
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, OVCAR-3
TumCMig↓, TumCI↓, NF-kB↓, p65↓, MMP9↓, eff↑, AntiTum↑, Inflam↓, AntiDiabetic↑,
7163- CHA,    The anticancer effects of chaetocin are independent of programmed cell death and hypoxia, and are associated with inhibition of endothelial cell proliferation
- in-vitro, Lung, A549 - in-vitro, OS, U2OS - in-vitro, CRC, HCT116 - in-vitro, CRC, HeLa - in-vivo, Ovarian, SKOV3
ROS↑, Trx↓, Apoptosis↑, TumCG↓, SUV39H↓, Hif1a↓, TumCP↓, eff↓, MMP↓, TumCG↓, Dose↝, toxicity↓,
2791- CHr,    Chrysin attenuates progression of ovarian cancer cells by regulating signaling cascades and mitochondrial dysfunction
- in-vitro, Ovarian, OV90
TumCP↓, TumCD↑, ROS↑, Ca+2↑, MMP↓, MAPK↑, PI3K↑, p‑Akt↑, PCNA↓, p‑p70S6↑, p‑ERK↑, p38↑, JNK↑, DNAdam↑, TumCCA↑, chemoP↑,
952- Cin,    Cinnamon Extract Reduces VEGF Expression Via Suppressing HIF-1α Gene Expression and Inhibits Tumor Growth in Mice
- in-vitro, BC, MDA-MB-231 - in-vitro, GBM, U251 - in-vivo, Ovarian, SKOV3
VEGF↓, Hif1a↓, p‑STAT3↓, p‑Akt↓, angioG↓, TumCG↓, TumW↓, ascitic↓,
1592- Citrate,    Inhibition of Mcl-1 expression by citrate enhances the effect of Bcl-xL inhibitors on human ovarian carcinoma cells
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, IGROV1
eff↑, tumCV↓, Mcl-1↓, eff↑,
1585- Citrate,    Sodium citrate targeting Ca2+/CAMKK2 pathway exhibits anti-tumor activity through inducing apoptosis and ferroptosis in ovarian cancer
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S - in-vitro, Nor, HEK293
Apoptosis↑, Ferroptosis↑, Ca+2↓, CaMKII ↓, Akt↓, mTOR↓, Hif1a↓, ROS↑, ChemoSen↑, Casp3↑, Casp9↑, BAX↑, Bcl-2↓, Cyt‑c↑, GlucoseCon↓, lactateProd↓, Pyruv↓, GLUT1↓, HK2↓, PFKP↓, Glycolysis↓, Hif1a↓, p‑Akt↓, p‑mTOR↓, Iron↑, lipid-P↑, MDA↑, ROS↑, H2O2↑, mtDam↑, GSH↓, GPx↓, GPx4↓, NADPH/NADP+↓, eff↓, FTH1↓, LC3‑Ⅱ/LC3‑Ⅰ↑, NCOA4↑, eff↓, TumCG↓,
4776- CoQ10,    Antitumor properties of Coenzyme Q0 against human ovarian carcinoma cells via induction of ROS-mediated apoptosis and cytoprotective autophagy
- vitro+vivo, Ovarian, SKOV3
ROS↑, eff↓, AntiCan↑, Apoptosis↑, tumCV↓, TumCG↓, TumCCA↑, LC3s↑, ERStress↑, Beclin-1↑, Bax:Bcl2↑, HER2/EBBR2↓, Akt↓, mTOR↓,
6292- Cro,    Crocetin induces cytotoxicity and enhances vincristine-induced cancer cell death via p53-dependent and -independent mechanisms
- in-vitro, Cerv, HeLa - in-vitro, Lung, A549 - in-vitro, Ovarian, SKOV3
TumCP↓, TumCCA↑, P21↑, Apoptosis↑, eff↑,
472- CUR,    Curcumin inhibits ovarian cancer progression by regulating circ-PLEKHM3/miR-320a/SMG1 axis
- vitro+vivo, Ovarian, SKOV3 - vitro+vivo, Ovarian, A2780S
TumCP↓, Apoptosis↑, PCNA↓, miR-320a↓, BAX↑, cl‑Casp3↑, circ‑PLEKHM3↑, SMG1↑,
471- CUR,    Curcumin induces apoptotic cell death and protective autophagy by inhibiting AKT/mTOR/p70S6K pathway in human ovarian cancer cells
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S
Apoptosis↑, TumAuto↑, p62↓, p‑Akt↓, p‑mTOR↓, p‑P70S6K↓, Casp9↑, PARP↑, ATG3↑, Beclin-1↑, LC3‑Ⅱ/LC3‑Ⅰ↑,
470- CUR,    Regulation of carcinogenesis and modulation through Wnt/β-catenin signaling by curcumin in an ovarian cancer cell line
- in-vitro, Ovarian, SKOV3
Wnt/(β-catenin)↓, EMT↓, DNMT3A↓, cycD1/CCND1↓, cMyc↓, Fibronectin↓, Vim↓, E-cadherin↑, SFRP5↑,
469- CUR,    The inhibitory effect of curcumin via fascin suppression through JAK/STAT3 pathway on metastasis and recurrence of ovary cancer cells
- in-vitro, Ovarian, SKOV3
fascin↓, STAT3↓, JAK↓,
1874- DCA,    Dichloroacetate induces apoptosis of epithelial ovarian cancer cells through a mechanism involving modulation of oxidative stress
- in-vitro, Ovarian, SKOV3 - in-vitro, Ovarian, MDAH-2774
Apoptosis↑, MPO↓, iNOS↓, Hif1a↓, SOD↑, Casp3↑,
2169- dietF,    Prolonged stabilization of platinum-resistant ovarian cancer in a single patient consuming a fermented soy therapy
- Case Report, Ovarian, NA
OS↑, CA125↓, eff↑,
6734- Dipy,  Cisplatin,    Adenosine enhances cisplatin sensitivity in human ovarian cancer cells
- in-vitro, Ovarian, NA
eff↑, eff↓, ADO↓,
6788- EGCG,    A systematic review and meta-analysis of the effects of green tea extracts and polyphenols in female hormone-dependent cancers for benefit-risk evaluation
- Review, BC, NA - Review, Ovarian, NA
TumVol↓, TumW↓, *toxicity↝,
4681- EGCG,    Epigallocatechin-3-Gallate Prevents the Acquisition of a Cancer Stem Cell Phenotype in Ovarian Cancer Tumorspheres through the Inhibition of Src/JAK/STAT3 Signaling
- in-vitro, Ovarian, ES-2
TumCP↓, Apoptosis↑, Nanog↓, SOX2↓, Fibronectin↓, CD133↓,
1247- EMD,    Emodin exerts antitumor effects in ovarian cancer cell lines by preventing the development of cancer stem cells via epithelial mesenchymal transition
- vitro+vivo, Ovarian, SKOV3 - in-vitro, Ovarian, A2780S
TumCP↓, TumCMig↓, TumCI↓, EMT↓, N-cadherin↓, Vim↓, E-cadherin↑, TumCG↓, CD133↓, OCT4↓, CSCs↓,
5047- erastin,    The ferroptosis inducer erastin irreversibly inhibits system xc− and synergizes with cisplatin to increase cisplatin’s cytotoxicity in cancer cells
- in-vitro, Ovarian, NA
xCT↓, GSH↓, Ferroptosis↑, ChemoSen↑, eff↑,
6855- FBZ,    Transcriptome analysis reveals the anticancer effects of fenbendazole on ovarian cancer: an in vitro and in vivo study
- vitro+vivo, Ovarian, A2780S - vitro+vivo, Ovarian, SKOV3
TumCP↓, Apoptosis↑, TumCG↓, cl‑Casp3↑, Bax:Bcl2↑, CDK1↓,
6970- Form,    Formononetin, an isoflavone from Astragalus membranaceus inhibits proliferation and metastasis of ovarian cancer cells
- in-vitro, Ovarian, NA
tumCV↓, Apoptosis↑, Casp3↑, Casp9↑, Bax:Bcl2↑, TumCMig↓, TumCI↓, MMP2↓, MMP9↓, p‑ERK↓,
947- GA,    Gallic acid, a phenolic compound, exerts anti-angiogenic effects via the PTEN/AKT/HIF-1α/VEGF signaling pathway in ovarian cancer cells
- in-vitro, Ovarian, OVCAR-3 - in-vitro, Melanoma, A2780S - in-vitro, Nor, IOSE364 - Human, NA, NA
TumCG↓, VEGF↓, angioG↓, p‑Akt↓, Hif1a↓, PTEN↑, BioAv↑, *toxicity↓,

Showing Research Papers: 1 to 50 of 107
Page 1 of 3 Next

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 107

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

ADO↓, 1,   COL4A3↓, 1,   CXCL6/GCP-2↓, 1,   miR-375↑, 1,   SUV39H↓, 1,   TYMP/ECGF1↓, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

Fenton↑, 1,   Ferroptosis↑, 2,   GPx↓, 1,   GPx4↓, 1,   GSH↓, 4,   GSH/GSSG↓, 1,   H2O2↑, 1,   HO-1↑, 1,   Iron↑, 1,   lipid-P↑, 1,   MDA↑, 1,   MPO↓, 1,   NADPH/NADP+↓, 1,   ROS↑, 17,   SOD↑, 1,   Trx↓, 1,   TrxR↓, 1,   xCT↓, 1,  

Metal & Cofactor Biology(tgid=2) ⓘ

FTH1↓, 1,   NCOA4↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

CDC25↓, 1,   MMP↓, 4,   MMP↑, 1,   mtDam↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

12LOX↓, 1,   cMyc↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 2,   HK2↓, 2,   HMG-CoA↓, 1,   lactateProd↓, 1,   LDH↓, 2,   PDK1↓, 1,   PFK2↓, 1,   PFKP↓, 1,   PKM2↓, 1,   Pyruv↓, 1,   Warburg↓, 1,  

Cell Death(tgid=5) ⓘ

Akt↓, 2,   p‑Akt↓, 6,   p‑Akt↑, 1,   Apoptosis↑, 16,   Bak↑, 1,   BAX↑, 3,   Bax:Bcl2↑, 4,   Bcl-2↓, 3,   Bcl-xL↓, 2,   BIM↑, 1,   Casp10∅, 1,   Casp3↑, 7,   cl‑Casp3↑, 3,   Casp7↑, 1,   Casp8∅, 1,   Casp9↑, 4,   Chk2↑, 1,   CK2↓, 1,   Cyt‑c↑, 3,   DR4∅, 1,   DR5∅, 1,   FADD∅, 1,   Ferroptosis↑, 2,   HEY1↓, 1,   iNOS↓, 1,   JNK↑, 1,   MAPK↓, 1,   MAPK↑, 1,   Mcl-1↓, 2,   p38↑, 1,   TumCD↑, 1,  

Kinase & Signal Transduction(tgid=6) ⓘ

CaMKII ↓, 1,   HER2/EBBR2↓, 1,   p‑p70S6↑, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

miR-145↑, 1,   miR-21↓, 1,   TET3↑, 1,   tumCV↓, 4,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,   ERStress↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

ATG3↑, 1,   Beclin-1↑, 3,   LC3‑Ⅱ/LC3‑Ⅰ↑, 2,   LC3B↑, 1,   LC3B-II↑, 1,   LC3s↑, 1,   lysosome↓, 1,   p62↓, 1,   TumAuto↑, 2,  

DNA Damage & Repair(tgid=10) ⓘ

CHK1↓, 1,   DNAdam↑, 5,   DNMT3A↓, 1,   P53↑, 1,   PARP↑, 1,   cl‑PARP↑, 2,   PCNA↓, 2,   SMG1↑, 1,   p‑γH2AX↑, 1,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK4∅, 1,   cycD1/CCND1↓, 3,   cycD1/CCND1∅, 1,   P21↑, 2,   Securin↓, 1,   TumCCA↑, 8,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

ALDH1A1↓, 1,   CD133↓, 2,   CD34↓, 1,   CD44↓, 1,   CSCs↓, 4,   EMT↓, 2,   p‑ERK↓, 1,   p‑ERK↑, 1,   Gli1↓, 1,   H3K27ac∅, 1,   HH↓, 1,   IGFR↓, 1,   mTOR↓, 2,   p‑mTOR↓, 2,   Nanog↓, 1,   NOTCH1↓, 1,   OCT4↓, 2,   p‑P70S6K↓, 1,   PDGFRB↓, 1,   PI3K↑, 1,   circ‑PLEKHM3↑, 1,   PTEN↑, 1,   SFRP5↑, 1,   SOX2↓, 1,   STAT3↓, 1,   p‑STAT3↓, 1,   TumCG↓, 14,   Wnt/(β-catenin)↓, 1,  

Migration(tgid=13) ⓘ

AXL↓, 1,   Ca+2↓, 1,   Ca+2↑, 1,   E-cadherin↑, 3,   FAK↓, 1,   fascin↓, 1,   Fibronectin↓, 2,   Ki-67↓, 1,   miR-130a↓, 1,   miR-320a↓, 1,   MMP11↓, 1,   MMP2↓, 1,   MMP9↓, 3,   N-cadherin↓, 1,   Snail↓, 1,   TumCI↓, 5,   TumCMig↓, 5,   TumCP↓, 12,   TumMeta↓, 1,   Tyro3↓, 1,   Vim↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 6,   EPR↑, 1,   Hif1a↓, 7,   VEGF↓, 3,   VEGFR2/KDR/Flk1↓, 1,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 2,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

IL1β↓, 1,   Inflam↓, 1,   JAK↓, 1,   NF-kB↓, 1,   p65↓, 1,   PD-L1↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

CDK6∅, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   ChemoSen↑, 5,   Dose↝, 3,   Dose∅, 1,   eff↓, 7,   eff↑, 12,   RadioS↑, 2,   selectivity↑, 2,  

Clinical Biomarkers(tgid=22) ⓘ

ascitic↓, 1,   CA125↓, 1,   GutMicro↑, 1,   HER2/EBBR2↓, 1,   Ki-67↓, 1,   LDH↓, 2,   PD-L1↓, 1,  

Functional Outcomes(tgid=23) ⓘ

AntiCan↑, 3,   AntiDiabetic↑, 1,   antiNeop↑, 1,   AntiTum↑, 1,   chemoP↑, 1,   OS↑, 1,   Strength↑, 1,   toxicity↓, 1,   TumVol↓, 1,   TumW↓, 3,  
Total Targets: 196

Pathway results for Effect on Normal Cells:


Protein Folding & ER Stress(tgid=8) ⓘ

UPR↑, 1,  

Functional Outcomes(tgid=23) ⓘ

cachexia↑, 1,   toxicity↓, 2,   toxicity↝, 1,  
Total Targets: 4

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells

Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:20  Cells:%  prod#:%  Target#:%  State#:%  Dir#:%
  wNotes=0  sortOrder:rid,rpid

 

Home Page